CANNABIS SCIENCE - Revolution oder Verblendung ?

www.otcmarkets.com/news/otc-market-headline?id=664054

www.smobserved.com/story/2016/12/01/news/...dule-one/2301.html

 ein kleiner Allgemeiner Artikel im Spiegel:

 

 m.spiegel.de/panorama/gesellschaft/...n0sRARzn6fTIE9NdZOBPf4dN

sehen wir nach den ersten monaten amtsantritt  

vor Kursexplosion heute.....

Bid ist höher als Schlußkurs gestern.
Auch bei anderen Cannabis Werten ähnliches Bild,
warten wir es mal ab ...

Wind kommt auf!
Und vorallem in die richtige Richtung.

Cannabis irgendwann legalisiert wird, dreht Arte noch einen Milieukrimi:
www.spiegel.de/kultur/tv/...-andere-als-bekifft-a-1125001.html
Bitte aber erst in 2-5 Jahren legalisieren, wenn CBIS schon Weltmarktführer ist.
2-25€ pro Schein, man kann träumen.

blogs.taz.de/drogerie/2016/11/18/...nche-cannabis-als-medizin/

Artikel:
bewusst-vegan-froh.de/...-und-hanf-nie-verboten-worden-waeren/
Man merkt deutlich das bei den Cannabis-Aktien Druck auf dem Kessel ist.

Aber solange es kein offizielles Statement von der neuen US-Regierung gibt wird nichts weiter passieren.

Man kann bloß hoffen  das Trump für Cannabis ist sollte es so sein wird es genauso knallen wie an Silvester ;)

Eine Verschärfung der Kriminalisierung ist fast undenkbar.
Am Tag seines Triumphes haben die Amerikaner auch für die Legalierung gestimmt, das wird er nicht vergessen. Er wird das Rad nicht zurückdrehen.

Ich stelle mir gerade einen bekifften amerikanischen Präsidenten vor, der seinen Kindern beibringt wie man Joints baut und dessen Berater ständig auf der Suche nach besonders wirksamen Cannabissorten "grown in USA" für den weltweiten Export sind, um endlich das Außenhandelsdefizit in den Griff zu bekommen.

Vom Kiffen oder der medizinischen Nutzung von Cannabis?
Obama hat gerne gekifft, die Trumps wohl eher nicht.

mit dem man Cbis auch in US traden kann?
Stuttgart und München sind ja fast eingeschlafen.

bin bei cortal consor und würde da gerne weg mit meinem CBIS Aktien  

Charting Another Run on Cannabis Science Inc (OTCMKTS:CBIS)
 0  
By James Elliot  on December 17, 2016   Media & Technology, Micro Cap Insider




Cannabis Science Inc (OTCMKTS:CBIS) has been moving up steadily since a brief dip below the $0.03 mark. The stock saw a recent pop to $0.077 as pot stocks heated up. The Company is one of the original Marijuana plays to hit the BB’s back in 2009. Over the past several years as Marijuana stocks have heated up CBIS has been at the forefront of this incredible phenomenon trading massive volume and rising to incredible highs.

CBIS is running fast as pot stocks have heated up going into the election. The red hot Marijuana industry has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with with many new states legalizing the drug including California, Nevada, Maine, and Massachusetts on November 8. Medical MJ products in the U.S. alone are projected to generate up to $35 Billion by 2020.

Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.

CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:

The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”

The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”

labor- und extraktionsstätte, haben 3 medikamente in phase 1 studie

Back in March CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.

The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.

CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.



On November 16 CBIS announced plans to initiate a long awaited medication study for Pulmonary Patients suffering from varying failing lung functions stemming from Cancers to Bronchitis and all in between respiratory ailments. “We expect it will begin as soon as the First Lab and Extraction site is completed and we think this will take place in this month of November,” stated CEO and Co-founder Raymond C. Dabney.

One of Cannabis Science’s goals along with medications are the delivery systems required and deemed to be the most beneficial to the patient. While medications in pill form and/or inhaled medications serve well for maintenance purposes and long term regimens, often times much of a medication’s healing benefit is lost through the delivery method. While this does not diminish the need for these maintenance type and quick relief medications, a targeted method for more serious times of the targeted disease is not only required but a necessity.

vorantreiben. mit eigenem labor und vielen kleinen investoren

vor start von eigenem labor

"The first quarter of 2017 will be an exciting time for more new product releases and much larger distribution channels. We will utilize various medication delivery methods (such as pills, creams, extracts, inhalers, tinctures, and balms) based on the ailment and we will release our cannabinoid-based medications across the country. I can't emphasis enough what an exciting and busy year 2017 looks to be," stated CBIS CEO Raymond C. Dabney.

Cannabis Science is mapping out strategic demographic analyses across the country for full circle operations in each area: Grow, Lab Extraction, Manufacturing and Dispensaries. Having R&D and full circle operations and facilities in one site will allow Cannabis Science to bring its product to market more rapidly than before, while trimming costs for acquisition, extraction, and medication manufacturing. While the company will place high emphasis on producing its existing product lines to meet the demand of current distributors, Cannabis Science will continue and expand the work on developing new product lines, which will allow them to access new patients across the country.

With over 3,500 acres in its portfolio in California and Nevada and much more under negotiations for future drug development projects, the company has a unique opportunity to scale out this model very quickly across the Western United States. Once this pilot buildout project in Nevada is complete and functional, the company will work on expanding its operations across the country.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to several illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
allen.herman@cannabisscience.com
Tel: 1-888-263-0832

Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832

Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
teresa@cannabisscience.com
Tel: 1-888-263-0832


News Provided by QuoteMedia.

Ausbruch Richtung 0,05ct/€...